Cargando…

(11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases

OBJECTIVES: Radiation-induced changes (RIC) secondary to focal radiotherapy can imitate tumour progression in brain metastases and make follow-up clinical decision making unreliable. (11)C-methyl-L-methionine-PET (MET-PET) is widely used for the diagnosis of RIC in brain metastases, but minimal lite...

Descripción completa

Detalles Bibliográficos
Autores principales: Govaerts, Chris W., van Dijken, Bart RJ., Stormezand, Gilles N., van der Weide, Hiske L., Wagemakers, Michiel, Enting, Roelien H., van der Hoorn, Anouk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327750/
https://www.ncbi.nlm.nih.gov/pubmed/34233489
http://dx.doi.org/10.1259/bjr.20210275
_version_ 1784757572520116224
author Govaerts, Chris W.
van Dijken, Bart RJ.
Stormezand, Gilles N.
van der Weide, Hiske L.
Wagemakers, Michiel
Enting, Roelien H.
van der Hoorn, Anouk
author_facet Govaerts, Chris W.
van Dijken, Bart RJ.
Stormezand, Gilles N.
van der Weide, Hiske L.
Wagemakers, Michiel
Enting, Roelien H.
van der Hoorn, Anouk
author_sort Govaerts, Chris W.
collection PubMed
description OBJECTIVES: Radiation-induced changes (RIC) secondary to focal radiotherapy can imitate tumour progression in brain metastases and make follow-up clinical decision making unreliable. (11)C-methyl-L-methionine-PET (MET-PET) is widely used for the diagnosis of RIC in brain metastases, but minimal literature exists regarding the optimum PET measuring parameter to be used. We analysed the diagnostic performance of different MET-PET measuring parameters in distinguishing between RIC and tumour progression in a retrospective cohort of brain metastasis patients. METHODS: 26 patients with 31 metastatic lesions were included on the basis of having undergone a PET scan due to radiological uncertainty of disease progression. The PET images were analysed and methionine uptake quantified using standardised-uptake-values (SUV) and tumour-to-normal tissue (T/N) ratios, generated as SUV(mean), SUV(max), SUV(peak), T/N(mean), T/N(max-mean) and T/N(peak-mean). Metabolic-tumour-volume and total-lesion methionine metabolism were also computed. A definitive diagnosis of either RIC or tumour progression was established by clinicoradiological follow-up of least 4 months subsequent to the investigative PET scan. RESULTS: All MET-PET parameters except metabolic-tumour-volume showed statistically significant differences between tumour progression and lesions with RIC. Receiver-operating-characteristic curve and area-under the-curve analysis demonstrated the highest value of 0.834 for SUV(max) with a corresponding optimum threshold of 3.29. This associated with sensitivity, specificity, positive predictive and negative predictive values of 78.57, 70.59%, 74.32 and 75.25% respectively. CONCLUSIONS: MET-PET is a useful modality for the diagnosis of RIC in brain metastases. SUV(max) was the PET parameter with the greatest diagnostic performance. ADVANCES IN KNOWLEDGE: More robust comparisons between SUV(max) and SUV(peak) could enhance follow-up treatment planning.
format Online
Article
Text
id pubmed-9327750
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The British Institute of Radiology.
record_format MEDLINE/PubMed
spelling pubmed-93277502022-08-05 (11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases Govaerts, Chris W. van Dijken, Bart RJ. Stormezand, Gilles N. van der Weide, Hiske L. Wagemakers, Michiel Enting, Roelien H. van der Hoorn, Anouk Br J Radiol Full Paper OBJECTIVES: Radiation-induced changes (RIC) secondary to focal radiotherapy can imitate tumour progression in brain metastases and make follow-up clinical decision making unreliable. (11)C-methyl-L-methionine-PET (MET-PET) is widely used for the diagnosis of RIC in brain metastases, but minimal literature exists regarding the optimum PET measuring parameter to be used. We analysed the diagnostic performance of different MET-PET measuring parameters in distinguishing between RIC and tumour progression in a retrospective cohort of brain metastasis patients. METHODS: 26 patients with 31 metastatic lesions were included on the basis of having undergone a PET scan due to radiological uncertainty of disease progression. The PET images were analysed and methionine uptake quantified using standardised-uptake-values (SUV) and tumour-to-normal tissue (T/N) ratios, generated as SUV(mean), SUV(max), SUV(peak), T/N(mean), T/N(max-mean) and T/N(peak-mean). Metabolic-tumour-volume and total-lesion methionine metabolism were also computed. A definitive diagnosis of either RIC or tumour progression was established by clinicoradiological follow-up of least 4 months subsequent to the investigative PET scan. RESULTS: All MET-PET parameters except metabolic-tumour-volume showed statistically significant differences between tumour progression and lesions with RIC. Receiver-operating-characteristic curve and area-under the-curve analysis demonstrated the highest value of 0.834 for SUV(max) with a corresponding optimum threshold of 3.29. This associated with sensitivity, specificity, positive predictive and negative predictive values of 78.57, 70.59%, 74.32 and 75.25% respectively. CONCLUSIONS: MET-PET is a useful modality for the diagnosis of RIC in brain metastases. SUV(max) was the PET parameter with the greatest diagnostic performance. ADVANCES IN KNOWLEDGE: More robust comparisons between SUV(max) and SUV(peak) could enhance follow-up treatment planning. The British Institute of Radiology. 2021-09-01 2021-08-18 /pmc/articles/PMC9327750/ /pubmed/34233489 http://dx.doi.org/10.1259/bjr.20210275 Text en © 2021 The Authors. Published by the British Institute of Radiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 Unported License http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial reuse, provided the original author and source are credited.
spellingShingle Full Paper
Govaerts, Chris W.
van Dijken, Bart RJ.
Stormezand, Gilles N.
van der Weide, Hiske L.
Wagemakers, Michiel
Enting, Roelien H.
van der Hoorn, Anouk
(11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases
title (11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases
title_full (11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases
title_fullStr (11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases
title_full_unstemmed (11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases
title_short (11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases
title_sort (11)c-methyl-l-methionine pet measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases
topic Full Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327750/
https://www.ncbi.nlm.nih.gov/pubmed/34233489
http://dx.doi.org/10.1259/bjr.20210275
work_keys_str_mv AT govaertschrisw 11cmethyllmethioninepetmeasuringparametersforthediagnosisoftumourprogressionagainstradiationinducedchangesinbrainmetastases
AT vandijkenbartrj 11cmethyllmethioninepetmeasuringparametersforthediagnosisoftumourprogressionagainstradiationinducedchangesinbrainmetastases
AT stormezandgillesn 11cmethyllmethioninepetmeasuringparametersforthediagnosisoftumourprogressionagainstradiationinducedchangesinbrainmetastases
AT vanderweidehiskel 11cmethyllmethioninepetmeasuringparametersforthediagnosisoftumourprogressionagainstradiationinducedchangesinbrainmetastases
AT wagemakersmichiel 11cmethyllmethioninepetmeasuringparametersforthediagnosisoftumourprogressionagainstradiationinducedchangesinbrainmetastases
AT entingroelienh 11cmethyllmethioninepetmeasuringparametersforthediagnosisoftumourprogressionagainstradiationinducedchangesinbrainmetastases
AT vanderhoornanouk 11cmethyllmethioninepetmeasuringparametersforthediagnosisoftumourprogressionagainstradiationinducedchangesinbrainmetastases